Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Avadel Pharmaceuticals

Nasdaq:AVDL
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AVDL
Nasdaq
$385M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Avadel Pharmaceuticals has significant price volatility in the past 3 months.
AVDL Share Price and Events
7 Day Returns
12.9%
NasdaqGM:AVDL
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
477.7%
NasdaqGM:AVDL
-2%
US Pharmaceuticals
-10%
US Market
AVDL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avadel Pharmaceuticals (AVDL) 12.9% 0.7% 18.4% 477.7% -13.5% -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • AVDL outperformed the Pharmaceuticals industry which returned -2% over the past year.
  • AVDL outperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
AVDL
Industry
5yr Volatility vs Market
Related Companies

AVDL Value

 Is Avadel Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Avadel Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Avadel Pharmaceuticals.

NasdaqGM:AVDL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:AVDL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 12.5%) (32.4%))
0.886
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.89
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.886 * 6.51%)
7.51%

Discounted Cash Flow Calculation for NasdaqGM:AVDL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Avadel Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:AVDL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.51%)
2020 -13.00 Analyst x1 -12.09
2021 -4.75 Analyst x2 -4.11
2022 26.45 Analyst x2 21.29
2023 67.40 Analyst x2 50.46
2024 106.70 Analyst x2 74.30
2025 138.21 Est @ 29.53% 89.53
2026 167.51 Est @ 21.2% 100.93
2027 193.24 Est @ 15.36% 108.30
2028 215.02 Est @ 11.27% 112.10
2029 233.11 Est @ 8.41% 113.05
Present value of next 10 years cash flows $653.00
NasdaqGM:AVDL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $233.11 × (1 + 1.74%) ÷ (7.51% – 1.74%)
$4,113.49
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,113.49 ÷ (1 + 7.51%)10
$1,994.80
NasdaqGM:AVDL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $653.00 + $1,994.80
$2,647.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,647.80 / 46.40
$57.06
NasdaqGM:AVDL Discount to Share Price
Calculation Result
Value per share (USD) From above. $57.06
Current discount Discount to share price of $8.29
= -1 x ($8.29 - $57.06) / $57.06
85.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Avadel Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $8.29 vs Future cash flow value of $57.06
Current Discount Checks
For Avadel Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Avadel Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Avadel Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avadel Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avadel Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AVDL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.89
NasdaqGM:AVDL Share Price ** NasdaqGM (2020-04-07) in USD $8.29
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avadel Pharmaceuticals.

NasdaqGM:AVDL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AVDL Share Price ÷ EPS (both in USD)

= 8.29 ÷ -0.89

-9.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avadel Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Avadel Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Avadel Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:AVDL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
60.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avadel Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avadel Pharmaceuticals's assets?
Raw Data
NasdaqGM:AVDL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.78
NasdaqGM:AVDL Share Price * NasdaqGM (2020-04-07) in USD $8.29
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:AVDL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AVDL Share Price ÷ Book Value per Share (both in USD)

= 8.29 ÷ -0.78

-10.65x

* Primary Listing of Avadel Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avadel Pharmaceuticals has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.
X
Value checks
We assess Avadel Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Avadel Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AVDL Future Performance

 How is Avadel Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avadel Pharmaceuticals expected to grow at an attractive rate?
  • Avadel Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Avadel Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Avadel Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AVDL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AVDL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 60.6%
NasdaqGM:AVDL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 34.8%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AVDL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AVDL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 283 128 144 3
2023-12-31 218 87 97 3
2022-12-31 140 40 50 3
2021-12-31 68 -28 -31 4
2020-12-31 42 -36 -36 5
2020-04-08
NasdaqGM:AVDL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 59 -38 -33
2019-09-30 69 -55 -94
2019-06-30 75 -67 -101
2019-03-31 86 -86 -96
2018-12-31 103 -83 -95
2018-09-30 117 -72 -40
2018-06-30 137 -55 -2
2018-03-31 154 -27 30
2017-12-31 173 17 68
2017-09-30 182 38 81
2017-06-30 174 37 40
2017-03-31 167 24 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Avadel Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Avadel Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AVDL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Avadel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AVDL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.33 3.08 0.94 3.00
2023-12-31 1.60 2.29 0.27 3.00
2022-12-31 0.85 1.53 -0.19 3.00
2021-12-31 -0.64 -0.08 -1.35 4.00
2020-12-31 -0.79 -0.55 -1.32 4.00
2020-04-08
NasdaqGM:AVDL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.89
2019-09-30 -2.53
2019-06-30 -2.72
2019-03-31 -2.60
2018-12-31 -2.55
2018-09-30 -1.05
2018-06-30 -0.06
2018-03-31 0.76
2017-12-31 1.69
2017-09-30 1.98
2017-06-30 0.96
2017-03-31 -0.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Avadel Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Avadel Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avadel Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AVDL Past Performance

  How has Avadel Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avadel Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avadel Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Avadel Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avadel Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Avadel Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avadel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AVDL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 59.22 -33.23 30.18 32.92
2019-09-30 69.14 -94.35 46.93 30.03
2019-06-30 74.74 -101.25 66.45 33.90
2019-03-31 86.41 -96.09 87.53 38.12
2018-12-31 103.27 -95.30 100.36 39.33
2018-09-30 117.10 -39.69 101.36 65.52
2018-06-30 136.95 -2.24 88.10 54.11
2018-03-31 154.03 30.13 72.68 32.27
2017-12-31 173.25 68.27 58.86 33.42
2017-09-30 181.58 81.25 46.49
2017-06-30 173.99 39.58 47.67
2017-03-31 166.54 -9.31 46.53
2016-12-31 150.25 -41.28 45.15 33.64
2016-09-30 151.73 27.51 40.30
2016-06-30 166.96 19.43 32.13
2016-03-31 176.70 22.53 26.71
2015-12-31 173.01 41.80 21.71
2015-09-30 127.29 -63.54 18.92
2015-06-30 87.01 -45.51 18.45
2015-03-31 42.72 -48.85 16.65
2014-12-31 14.98 -89.49 15.70
2014-09-30 3.84 -55.56 16.78
2014-06-30 2.39 -51.89 15.60
2014-03-31 3.62 -64.54 14.24
2013-12-31 4.18 -46.51 13.22
2013-09-30 23.57 -38.95 10.44
2013-06-30 23.39 -39.01 10.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avadel Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Avadel Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avadel Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avadel Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avadel Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AVDL Health

 How is Avadel Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avadel Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avadel Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Avadel Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Avadel Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Avadel Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avadel Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:AVDL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -29.20 121.69 64.16
2019-09-30 -26.96 120.17 72.45
2019-06-30 -17.78 118.74 79.26
2019-03-31 -9.58 117.28 79.85
2018-12-31 2.78 115.84 103.27
2018-09-30 65.74 114.49 125.26
2018-06-30 78.55 113.15 147.11
2018-03-31 87.05 111.84 198.18
2017-12-31 85.58 0.27 97.43
2017-09-30 96.46 0.92 115.61
2017-06-30 76.73 0.89 173.80
2017-03-31 59.08 0.83 179.21
2016-12-31 42.07 0.82 154.20
2016-09-30 36.83 1.02 149.67
2016-06-30 51.84 1.07 154.86
2016-03-31 69.70 1.16 159.95
2015-12-31 69.13 1.12 144.80
2015-09-30
2015-06-30 13.64 150.03 116.12
2015-03-31 22.25 128.19 113.17
2014-12-31 24.90 9.10 92.83
2014-09-30 40.05 102.34 76.50
2014-06-30 57.86 94.66 77.86
2014-03-31 78.13 82.15 83.52
2013-12-31 -9.51 98.75 7.04
2013-09-30 -15.41 85.76 9.28
2013-06-30 -10.06 109.05 9.72
  • Avadel Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Avadel Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Avadel Pharmaceuticals has sufficient cash runway for 1.7 years based on current free cash flow.
  • Unable to confirm if Avadel Pharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Avadel Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avadel Pharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AVDL Dividends

 What is Avadel Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avadel Pharmaceuticals dividends.
If you bought $2,000 of Avadel Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avadel Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avadel Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AVDL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AVDL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avadel Pharmaceuticals has not reported any payouts.
  • Unable to verify if Avadel Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avadel Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avadel Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avadel Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avadel Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avadel Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AVDL Management

 What is the CEO of Avadel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Greg Divis
AGE 52
TENURE AS CEO 1.3 years
CEO Bio

Mr. Gregory J. Divis Jr., also known as Greg, has been the Chief Executive Officer and Director of Avadel Pharmaceuticals plc since June 3, 2019. Mr. Divis served as an Interim Chief Executive Officer at Avadel Pharmaceuticals plc since January 2019 until June 3, 2019. Mr. Divis served as Chief Operating Officer and Executive Vice President at Avadel Pharmaceuticals plc since March 22, 2018 until December 2018. Mr. Divis served as Chief Commercial Officer at Avadel Pharmaceuticals plc (Also known as: Flamel Technologies SA) since January 3, 2017. Prior to Avadel Mr. Divis served as an Executive-in-Residence and Operating Partner for Linden Capital, a healthcare-focused middle market private equity firm. Previous roles also include President and Chief Executive Officer of Lumara Health, a specialty-branded pharmaceutical company focused on women's health, where Mr. Divis led the successful turnaround and transformation of the business resulting in a series of transactions culminating in the successful sale to AMAG Pharmaceuticals. Mr. Divis has also held such notable roles as Vice President, Business Development Lifecycle Management at Sanofi-Aventis, and Vice-President and General Manager, UK and Ireland, for Schering-Plough Corporation. He currently serves on the Board of Directors of Mobius Therapeutics and previously served on the Board of Tolero Pharmaceuticals. Mr. Divis leads activities to establish external partnerships for a select group of its proprietary products and build Flamel's internal strategic pipeline through acquisitions of products and technologies. He has been Director of Jaguar Health, Inc. since June 2018. Mr. Divis served as the Chief Executive Officer and President of K-V Pharmaceutical Company since November 17, 2010 and served as its Interim President from June 10, 2010 to November 17, 2010. He served as President of Nesher Pharmaceuticals Inc. Mr. Divis served as the President of DrugTech Corporation and K-V Generic Pharmaceuticals, Inc. Mr. Divis served as the President of Ther-Rx Corporation, a wholly-owned subsidiary of K-V Pharmaceutical Company from July 2007 to November 2010. He served as an Interim Chief Executive Officer at K-V Pharmaceutical Company from July 10, 2010 to November 17, 2010. Mr. Divis served as Vice President of Business Development and Life Cycle Management at Sanofi-aventis U.S., from February 2006 to July 2007. He served as Vice President of Sales, Respiratory East at Sanofi-aventis U.S., from June 2004 to February 2006. He served as an Executive Director of Sales and Marketing National Accounts at Reliant Pharmaceuticals from December 2003 to June 2004. He served as Vice President and Country Manager, United Kingdom and Ireland at Schering-Plough from May 2002 to December 2003. Mr. Divis served as Vice President of Field Operations, Oncology-Biotech Division at Schering-Plough from October 2000 to April 2002. He has been of K-V Pharmaceutical Company since September 16, 2013. He is a Director of Lumara Health, Inc. Mr. Divis has more than 25 years of experience in the pharmaceutical industry. He holds a Bachelor's Degree from University of Iowa.

CEO Compensation
  • Insufficient data for Greg to compare compensation growth.
  • Insufficient data for Greg to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Avadel Pharmaceuticals management team in years:

2.5
Average Tenure
53
Average Age
  • The tenure for the Avadel Pharmaceuticals management team is about average.
Management Team

Phil Thompson

TITLE
Senior VP
COMPENSATION
$450K
AGE
45
TENURE
6.4 yrs

Gregg Davis

TITLE
VP of Corporate and Business Development
COMPENSATION
$685K
AGE
54
TENURE
4.8 yrs

Greg Divis

TITLE
CEO & Director
AGE
52
TENURE
1.3 yrs

Tom McHugh

TITLE
Chief Financial Officer
AGE
54
TENURE
0.3 yrs

Mark Elrod

TITLE
Vice President of Sales
TENURE
3.7 yrs

Séverine Martin

TITLE
Director of Human Resources and Corporate Projects
TENURE
5.7 yrs

Christian Kalita

TITLE
Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs

Steve Sullivan

TITLE
VP of Sales & Marketing and Head of Commercial Operations
AGE
54

Jordan Dubow

TITLE
Chief Medical Officer
AGE
41
TENURE
1 yrs

Jason Vaughn

TITLE
Senior Vice President of Technical Operations
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Avadel Pharmaceuticals board of directors in years:

1.5
Average Tenure
55.5
Average Age
  • The average tenure for the Avadel Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Geoff Glass

TITLE
Non-Executive Chairman of the Board
COMPENSATION
$214K
AGE
45
TENURE
1.3 yrs

Greg Divis

TITLE
CEO & Director
AGE
52
TENURE
0.8 yrs

Catherine Bréchignac

TITLE
Chairman of Scientific Advisory Board
AGE
72

Peter Thornton

TITLE
Independent Director
COMPENSATION
$227K
AGE
54
TENURE
2.8 yrs

Linda Palczuk

TITLE
Independent Director
COMPENSATION
$214K
AGE
57
TENURE
1.8 yrs

Eric Ende

TITLE
Independent Director
AGE
50
TENURE
1.3 yrs

Christian Trepo

TITLE
Member of Scientific Advisory Board
TENURE
15.3 yrs

Jean-Marie Lehn

TITLE
Member of Scientific Advisory Board
AGE
80
TENURE
15.3 yrs

Patrick Couvreur

TITLE
Member of Scientific Advisory Board

Mark McCamish

TITLE
Director
AGE
66
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
16. Dec 19 Sell Sandra Hatten Individual 12. Dec 19 12. Dec 19 -3,072 $7.23 $-22,211
05. Dec 19 Buy Eric Ende Individual 04. Dec 19 04. Dec 19 10,000 $5.97 $59,700
05. Dec 19 Buy Linda Palczuk Individual 03. Dec 19 03. Dec 19 7,500 $5.91 $44,325
19. Nov 19 Buy Geoffrey Glass Individual 15. Nov 19 18. Nov 19 20,000 $4.99 $99,800
19. Nov 19 Buy Gregory Divis Individual 15. Nov 19 15. Nov 19 19,000 $5.13 $97,470
19. Nov 19 Buy Eric Ende Individual 15. Nov 19 15. Nov 19 10,000 $4.98 $49,762
X
Management checks
We assess Avadel Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avadel Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AVDL News

Simply Wall St News

Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) A Volatile Stock?

If you own shares in Avadel Pharmaceuticals plc (NASDAQ:AVDL) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Check out our latest analysis for Avadel Pharmaceuticals What AVDL's beta value tells investors Given that it has a beta of 1.4, we can surmise that the Avadel Pharmaceuticals share price has been fairly sensitive to market volatility (over the last 5 years).

Simply Wall St -

Have Insiders Been Buying Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares?

See our latest analysis for Avadel Pharmaceuticals Avadel Pharmaceuticals Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by CEO & Director Gregory Divis for US$96k worth of shares, at about US$6.00 per share. … NasdaqGM:AVDL Recent Insider Trading, June 20th 2019 Avadel Pharmaceuticals is not the only stock that insiders are buying. … While we have no worries about the insider transactions, we'd be more comfortable if they owned more Avadel Pharmaceuticals stock.

Simply Wall St -

Do Directors Own Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares?

View our latest analysis for Avadel Pharmaceuticals NasdaqGM:AVDL Ownership Summary, June 20th 2019 What Does The Institutional Ownership Tell Us About Avadel Pharmaceuticals? … We can see that Avadel Pharmaceuticals does have institutional investors; and they hold 38% of the stock. … Insider Ownership Of Avadel Pharmaceuticals The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Did Changing Sentiment Drive Avadel Pharmaceuticals's (NASDAQ:AVDL) Share Price Down A Painful 79%?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) shareholders should be happy to see the share price up 24% in the last month. … View our latest analysis for Avadel Pharmaceuticals Avadel Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In just one year Avadel Pharmaceuticals saw its revenue fall by 44%.

Simply Wall St -

Before You Buy Avadel Pharmaceuticals plc (NASDAQ:AVDL), Consider Its Volatility

If you're interested in Avadel Pharmaceuticals plc (NASDAQ:AVDL), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

What Type Of Shareholder Owns Avadel Pharmaceuticals plc's (NASDAQ:AVDL)?

If you want to know who really controls Avadel Pharmaceuticals plc (NASDAQ:AVDL), then you'll have to look at the makeup of its share registry. … Avadel Pharmaceuticals is a smaller company with a market capitalization of US$99m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Balance Sheet A Threat To Its Future?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a small-cap stock with a market capitalization of US$230.76m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Companies operating in the Pharmaceuticals industry,.

Simply Wall St -

Who Are The Top Investors In Avadel Pharmaceuticals plc (NASDAQ:AVDL)?

I am going to take a deep dive into Avadel Pharmaceuticals plc’s (NASDAQ:AVDL) most recent ownership structure, not a frequent subject of discussion among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine AVDL's ownership structure in more detail.

Simply Wall St -

Should You Be Tempted To Buy Avadel Pharmaceuticals plc (NASDAQ:AVDL) At Its Current PE Ratio?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to better understand how you can grow your money by investing in Avadel Pharmaceuticals plc (NASDAQ:AVDL). … Avadel Pharmaceuticals plc (NASDAQ:AVDL) trades with a trailing P/E of 9.8x, which is lower than the industry average of 24x.

Simply Wall St -

Does Avadel Pharmaceuticals plc's (NASDAQ:AVDL) PE Ratio Signal A Buying Opportunity?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for AVDL Price per share = $7.07 Earnings per share = $1.687 ∴ Price-Earnings Ratio = $7.07 ÷ $1.687 = 4.2x The P/E ratio itself doesn’t tell you a lot; however, it becomes very insightful when you compare it with other similar companies. … For example, if you inadvertently compared lower risk firms with AVDL, then investors would naturally value AVDL at a lower price since it is a riskier investment. … Similarly, if you accidentally compared higher growth firms with AVDL, investors would also value AVDL at a lower price since it is a lower growth investment.

Simply Wall St -

AVDL Company Info

Description

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Details
Name: Avadel Pharmaceuticals plc
AVDL
Exchange: NasdaqGM
Founded: 2015
$384,692,741
46,404,432
Website: http://www.avadel.com
Address: Avadel Pharmaceuticals plc
Blanchardstown Corporate Park,
Block 10-1,
Dublin,
Co. Dublin, 15,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AVDL SPON ADR EACH REP 1 ORD SHS Nasdaq Global Market US USD 03. Jan 2017
DB AWK1 SPON ADR EACH REP 1 ORD SHS Deutsche Boerse AG DE EUR 03. Jan 2017
Number of employees
Current staff
Staff numbers
50
Avadel Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 11:05
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.